Epilepsy and cannabidiol: a guide to treatment: Epileptic Disorders

A. Arzimanoglou, U. Brandl, J.H. Cross, A. Gil-Nagel, L. Lagae, C.J. Landmark, N. Specchio, R. Nabbout, E.A. Thiele, O. Gubbay, and other members of The Cannabinoids International Experts Panel

Research output: Contribution to journalArticlepeer-review

Abstract

The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy. © 2020 Epileptic Disorders
Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalEpileptic Disord.
Volume22
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • cannabidiol
  • cannabis
  • CBD
  • Dravet
  • Epidiolex
  • Epidyolex
  • epilepsy
  • guidelines
  • Lennox-Gastaut
  • oil
  • bedica
  • bediol
  • bedrobinol
  • bedrocan
  • bedrolite
  • bedropuur
  • cannabichromene
  • cannabidivarin
  • cannabigerol
  • carbamazepine
  • clobazam
  • dronabinol
  • felbamate
  • lamotrigine
  • nabiximols
  • norclobazam
  • pedanios
  • perampanel
  • phenytoin
  • placebo
  • rufinamide
  • stiripentol
  • terpene
  • tetrahydrocannabinol
  • topiramate
  • unclassified drug
  • unindexed drug
  • valproic acid
  • zonisamide
  • cannabinoid receptor affecting agent
  • Aicardi syndrome
  • appetite disorder
  • Article
  • ataxia
  • behavior disorder
  • body weight change
  • Cannabis sativa
  • cannabis use
  • clinical effectiveness
  • Clinical Global Impression scale
  • convulsion
  • diarrhea
  • drug bioavailability
  • drug labeling
  • drug withdrawal
  • epileptic state
  • fatigue
  • fever
  • Food and Drug Administration
  • helplessness
  • human
  • International Organization for Standardization
  • intractable epilepsy
  • law
  • Lennox Gastaut syndrome
  • lethargy
  • liver dysfunction
  • mental disease
  • mood disorder
  • motor dysfunction
  • nausea
  • nonhuman
  • pancreatitis
  • pharyngitis
  • practice guideline
  • priority journal
  • quality of life assessment
  • randomized controlled trial (topic)
  • rash
  • recreational therapy
  • severe myoclonic epilepsy in infancy
  • sleep disorder
  • somnolence
  • therapeutic index
  • tuberous sclerosis
  • upper respiratory tract infection
  • vomiting
  • drug resistant epilepsy
  • myoclonus epilepsy
  • Cannabidiol
  • Cannabinoid Receptor Modulators
  • Drug Resistant Epilepsy
  • Epilepsies, Myoclonic
  • Humans
  • Lennox Gastaut Syndrome
  • Practice Guidelines as Topic

Fingerprint Dive into the research topics of 'Epilepsy and cannabidiol: a guide to treatment: Epileptic Disorders'. Together they form a unique fingerprint.

Cite this